Interlenkin-2 alone and in combination with other cytokines in melanoma

the investigational approach at the University of Texas M. D. Anderson Cancer Center

D. R. Parkinson, M. Talpaz, K. H. Lee, S. Legha, Avi Markowitz, K. Itoh, C. M. Balch, J. L. Murray, A. A. Zukiwski, R. S. Benjamin, J. U. Gutterman

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    The clinical data that have been accumulated so far suggests a significant influence of IL-2 dose and schedule on the immunobiological effects and clinical toxicities observed with this cytokine. Consequently, the series of Phase I and Phase II clinical trials conducted at the University of Texas M. D. Anderson Cancer Center in patients with advanced malignant melanoma investigating the use of IL-2 in combination with other cytokines, monoclonal antibodies, or ex vivo activated effector cells have used a common dose and schedule of IL-2 administration for which abundant immunobiological information already exists. This approach allows cross-trial comparison of experience with toxicities, immunobiological observations and clinical activity by a group of investigatiors within a single institution, and more rapid and valid evolution towards combination biological therapy, which preclinical data suggest will have greater activity than single agent therapy.

    Original languageEnglish
    Pages (from-to)39-48
    Number of pages10
    JournalCancer Treatment Reviews
    Volume16
    Issue numberSUPPL. A
    DOIs
    StatePublished - 1989

    Fingerprint

    Interleukin-2
    Melanoma
    Cytokines
    Appointments and Schedules
    Neoplasms
    Phase II Clinical Trials
    Biological Therapy
    Monoclonal Antibodies
    Therapeutics

    ASJC Scopus subject areas

    • Oncology
    • Urology

    Cite this

    Interlenkin-2 alone and in combination with other cytokines in melanoma : the investigational approach at the University of Texas M. D. Anderson Cancer Center. / Parkinson, D. R.; Talpaz, M.; Lee, K. H.; Legha, S.; Markowitz, Avi; Itoh, K.; Balch, C. M.; Murray, J. L.; Zukiwski, A. A.; Benjamin, R. S.; Gutterman, J. U.

    In: Cancer Treatment Reviews, Vol. 16, No. SUPPL. A, 1989, p. 39-48.

    Research output: Contribution to journalArticle

    Parkinson, DR, Talpaz, M, Lee, KH, Legha, S, Markowitz, A, Itoh, K, Balch, CM, Murray, JL, Zukiwski, AA, Benjamin, RS & Gutterman, JU 1989, 'Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center', Cancer Treatment Reviews, vol. 16, no. SUPPL. A, pp. 39-48. https://doi.org/10.1016/0305-7372(89)90021-2
    Parkinson, D. R. ; Talpaz, M. ; Lee, K. H. ; Legha, S. ; Markowitz, Avi ; Itoh, K. ; Balch, C. M. ; Murray, J. L. ; Zukiwski, A. A. ; Benjamin, R. S. ; Gutterman, J. U. / Interlenkin-2 alone and in combination with other cytokines in melanoma : the investigational approach at the University of Texas M. D. Anderson Cancer Center. In: Cancer Treatment Reviews. 1989 ; Vol. 16, No. SUPPL. A. pp. 39-48.
    @article{b5b75e3f1d3f48b8872df71816981884,
    title = "Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center",
    abstract = "The clinical data that have been accumulated so far suggests a significant influence of IL-2 dose and schedule on the immunobiological effects and clinical toxicities observed with this cytokine. Consequently, the series of Phase I and Phase II clinical trials conducted at the University of Texas M. D. Anderson Cancer Center in patients with advanced malignant melanoma investigating the use of IL-2 in combination with other cytokines, monoclonal antibodies, or ex vivo activated effector cells have used a common dose and schedule of IL-2 administration for which abundant immunobiological information already exists. This approach allows cross-trial comparison of experience with toxicities, immunobiological observations and clinical activity by a group of investigatiors within a single institution, and more rapid and valid evolution towards combination biological therapy, which preclinical data suggest will have greater activity than single agent therapy.",
    author = "Parkinson, {D. R.} and M. Talpaz and Lee, {K. H.} and S. Legha and Avi Markowitz and K. Itoh and Balch, {C. M.} and Murray, {J. L.} and Zukiwski, {A. A.} and Benjamin, {R. S.} and Gutterman, {J. U.}",
    year = "1989",
    doi = "10.1016/0305-7372(89)90021-2",
    language = "English",
    volume = "16",
    pages = "39--48",
    journal = "Cancer Treatment Reviews",
    issn = "0305-7372",
    publisher = "W.B. Saunders Ltd",
    number = "SUPPL. A",

    }

    TY - JOUR

    T1 - Interlenkin-2 alone and in combination with other cytokines in melanoma

    T2 - the investigational approach at the University of Texas M. D. Anderson Cancer Center

    AU - Parkinson, D. R.

    AU - Talpaz, M.

    AU - Lee, K. H.

    AU - Legha, S.

    AU - Markowitz, Avi

    AU - Itoh, K.

    AU - Balch, C. M.

    AU - Murray, J. L.

    AU - Zukiwski, A. A.

    AU - Benjamin, R. S.

    AU - Gutterman, J. U.

    PY - 1989

    Y1 - 1989

    N2 - The clinical data that have been accumulated so far suggests a significant influence of IL-2 dose and schedule on the immunobiological effects and clinical toxicities observed with this cytokine. Consequently, the series of Phase I and Phase II clinical trials conducted at the University of Texas M. D. Anderson Cancer Center in patients with advanced malignant melanoma investigating the use of IL-2 in combination with other cytokines, monoclonal antibodies, or ex vivo activated effector cells have used a common dose and schedule of IL-2 administration for which abundant immunobiological information already exists. This approach allows cross-trial comparison of experience with toxicities, immunobiological observations and clinical activity by a group of investigatiors within a single institution, and more rapid and valid evolution towards combination biological therapy, which preclinical data suggest will have greater activity than single agent therapy.

    AB - The clinical data that have been accumulated so far suggests a significant influence of IL-2 dose and schedule on the immunobiological effects and clinical toxicities observed with this cytokine. Consequently, the series of Phase I and Phase II clinical trials conducted at the University of Texas M. D. Anderson Cancer Center in patients with advanced malignant melanoma investigating the use of IL-2 in combination with other cytokines, monoclonal antibodies, or ex vivo activated effector cells have used a common dose and schedule of IL-2 administration for which abundant immunobiological information already exists. This approach allows cross-trial comparison of experience with toxicities, immunobiological observations and clinical activity by a group of investigatiors within a single institution, and more rapid and valid evolution towards combination biological therapy, which preclinical data suggest will have greater activity than single agent therapy.

    UR - http://www.scopus.com/inward/record.url?scp=0024456154&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0024456154&partnerID=8YFLogxK

    U2 - 10.1016/0305-7372(89)90021-2

    DO - 10.1016/0305-7372(89)90021-2

    M3 - Article

    VL - 16

    SP - 39

    EP - 48

    JO - Cancer Treatment Reviews

    JF - Cancer Treatment Reviews

    SN - 0305-7372

    IS - SUPPL. A

    ER -